From Big To Specialty — The Operational Transformation Of Bristol-Myers Squibb
Source: Life Science Leader
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
When Lou Schmukler joined Bristol-Myers Squibb (BMS) in 2011, it was analogous to jumping onto a moving train. The company’s biopharma transformation was barreling ahead at full steam. Launched in 2007, the business strategy to take the best of biotech and best of pharma had reshaped BMS from a big, diversified pharmaceutical company into a focused specialty biopharma firm, and they weren’t done yet. More change was coming, and the company’s manufacturing operations would need to move fast to keep up.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more